Literature DB >> 27377160

Bladder cancer: ASCO endorses EAU muscle-invasive bladder cancer guidelines.

Seth P Lerner1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27377160     DOI： 10.1038/nrurol.2016.114

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  9 in total

Review 1.  The RAZOR (randomized open vs robotic cystectomy) trial: study design and trial update.

Authors:  Norm D Smith; Erik P Castle; Mark L Gonzalgo; Robert S Svatek; Alon Z Weizer; Jeffrey S Montgomery; Raj S Pruthi; Michael E Woods; Matthew K Tollefson; Badrinath R Konety; Ahmad Shabsigh; Tracey Krupski; Daniel A Barocas; Atreya Dash; Marcus L Quek; Adam S Kibel; Dipen J Parekh
Journal:  BJU Int       Date:  2015-02       Impact factor: 5.588

2.  Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists.

Authors: 
Journal:  Lancet       Date:  1999-08-14       Impact factor: 79.321

3.  Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.

Authors:  Woonyoung Choi; Sima Porten; Seungchan Kim; Daniel Willis; Elizabeth R Plimack; Jean Hoffman-Censits; Beat Roth; Tiewei Cheng; Mai Tran; I-Ling Lee; Jonathan Melquist; Jolanta Bondaruk; Tadeusz Majewski; Shizhen Zhang; Shanna Pretzsch; Keith Baggerly; Arlene Siefker-Radtke; Bogdan Czerniak; Colin P N Dinney; David J McConkey
Journal:  Cancer Cell       Date:  2014-02-10       Impact factor: 31.743

4.  Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial.

Authors:  Bernard H Bochner; Guido Dalbagni; Daniel D Sjoberg; Jonathan Silberstein; Gal E Keren Paz; S Machele Donat; Jonathan A Coleman; Sheila Mathew; Andrew Vickers; Geoffrey C Schnorr; Michael A Feuerstein; Bruce Rapkin; Raul O Parra; Harry W Herr; Vincent P Laudone
Journal:  Eur Urol       Date:  2014-12-08       Impact factor: 20.096

5.  Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.

Authors:  Eliezer M Van Allen; Kent W Mouw; Philip Kim; Gopa Iyer; Nikhil Wagle; Hikmat Al-Ahmadie; Cong Zhu; Irina Ostrovnaya; Gregory V Kryukov; Kevin W O'Connor; John Sfakianos; Ilana Garcia-Grossman; Jaegil Kim; Elizabeth A Guancial; Richard Bambury; Samira Bahl; Namrata Gupta; Deborah Farlow; Angela Qu; Sabina Signoretti; Justine A Barletta; Victor Reuter; Jesse Boehm; Michael Lawrence; Gad Getz; Philip Kantoff; Bernard H Bochner; Toni K Choueiri; Dean F Bajorin; David B Solit; Stacey Gabriel; Alan D'Andrea; Levi A Garraway; Jonathan E Rosenberg
Journal:  Cancer Discov       Date:  2014-08-05       Impact factor: 39.397

6.  The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: A time-series analysis.

Authors:  Madhur Nayan; Bimal Bhindi; Julie L Yu; Muhammad Mamdani; Neil E Fleshner; Thomas Hermanns; Peter Chung; Michael Milosevic; Robert Bristow; Padraig Warde; Robert J Hamilton; Antonio Finelli; Michael A S Jewett; Alexandre R Zlotta; Srikala S Sridhar; Girish S Kulkarni
Journal:  Can Urol Assoc J       Date:  2016 Jan-Feb       Impact factor: 1.862

7.  Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base.

Authors:  Phillip J Gray; Stacey A Fedewa; William U Shipley; Jason A Efstathiou; Chun Chieh Lin; Anthony L Zietman; Katherine S Virgo
Journal:  Eur Urol       Date:  2012-11-19       Impact factor: 20.096

8.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Authors:  H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2003-08-28       Impact factor: 91.245

9.  Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement.

Authors:  Matthew I Milowsky; R Bryan Rumble; Christopher M Booth; Timothy Gilligan; Libni J Eapen; Ralph J Hauke; Pat Boumansour; Cheryl T Lee
Journal:  J Clin Oncol       Date:  2016-03-21       Impact factor: 44.544
  9 in total
  5 in total

1.  A novel bladder cancer - specific oncolytic adenovirus by CD46 and its effect combined with cisplatin against cancer cells of CAR negative expression.

Authors:  Wenjuan Cao; Junqiang Tian; Chong Li; Yanjun Gao; Xingchen Liu; Jianzhong Lu; Yuhan Wang; Zhiping Wang; Robert S Svatek; Ronald Rodriguez
Journal:  Virol J       Date:  2017-08-08       Impact factor: 4.099

2.  Synchronous presentation of muscle-invasive urothelial carcinoma of bladder and peritoneal malign mesothelioma.

Authors:  Cem Basatac; Fatma Aktepe; Sezer Sağlam; Haluk Akpınar
Journal:  Int Braz J Urol       Date:  2019 Jul-Aug       Impact factor: 1.541

3.  Risk-stratified surveillance and cost effectiveness of follow-up after radical cystectomy in patients with muscle-invasive bladder cancer.

Authors:  Ayumu Kusaka; Shingo Hatakeyama; Shogo Hosogoe; Itsuto Hamano; Hiromichi Iwamura; Naoki Fujita; Ken Fukushi; Takuma Narita; Kazuhisa Hagiwara; Hayato Yamamoto; Yuki Tobisawa; Tohru Yoneyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Takuya Koie; Hiroyuki Ito; Kazuaki Yoshikawa; Toshiaki Kawaguchi; Chikara Ohyama
Journal:  Oncotarget       Date:  2017-07-06

Review 4.  Asymptomatic recurrence detection and cost-effectiveness in urothelial carcinoma.

Authors:  Hiromichi Iwamura; Shingo Hatakeyama; Makoto Sato; Chikara Ohyama
Journal:  Med Oncol       Date:  2018-05-09       Impact factor: 3.064

5.  The prognostic value of routine preoperative blood parameters in muscle-invasive bladder cancer.

Authors:  Jingqi Zhang; Xiaozhou Zhou; Hua Ding; Liwei Wang; Sha Liu; Yuting Liu; Zhiwen Chen
Journal:  BMC Urol       Date:  2020-03-19       Impact factor: 2.264
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.